^
    1year
    PARALLEL TESTING OF LIQUID BIOPSY (CTDNA) AND TISSUE BIOPSY SAMPLES REVEALS A HIGHER FREQUENCY OF TARGETABLE EZH2 MUTATIONS IN FOLLICULAR LYMPHOMA (EHA 2023)
    In this study, we performed an in-depth spatio-temporal analysis of EZH2 mutations in FL using tissue- and liquid biopsy samples and identified gain-of-function mutations in a considerably higher proportion of patients than previously reported (42% vs 27%) owing to the ability of this approach to resolve spatial heterogeneity. This expands the subset of FL patients who most likely would benefit from EZH2 inhibitor therapy and highlights the need for parallel EZH2 testing in LB and TB samples when considering EZH2 inhibitor therapy. EZH2, ctDNA, Follicular lymphoma
    Liquid biopsy • Circulating tumor DNA • Biopsy
    |
    EZH2 mutation • EZH2 A682G • EZH2 Y646 • EZH2 Y646F